Esmolol: Difference between revisions
Gerald Chi- (talk | contribs) |
Gerald Chi- (talk | contribs) |
||
| Line 21: | Line 21: | ||
====BREVIBLOC (esmolol hydrochloride) injection==== | ====BREVIBLOC (esmolol hydrochloride) injection==== | ||
''' | ''' [[Esmolol indications and usage|Indications and Usage]]''' | ||
'''| [[Esmolol dosage and administration|Dosage and Administration]]''' | '''| [[Esmolol dosage and administration|Dosage and Administration]]''' | ||
'''| [[Esmolol dosage forms and strengths|Dosage Forms and Strengths]]''' | '''| [[Esmolol dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
'''| [[Esmolol contraindications|Contraindications]]''' | '''| [[Esmolol contraindications|Contraindications]]''' | ||
'''| [[Esmolol warnings|Warnings and Precautions]]''' | '''| [[Esmolol warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Esmolol adverse reactions|Adverse Reactions]]''' | '''| [[Esmolol adverse reactions|Adverse Reactions]]''' | ||
'''| [[Esmolol drug interactions|Drug Interactions]]''' | '''| [[Esmolol drug interactions|Drug Interactions]]''' | ||
Revision as of 22:39, 20 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]; Abdurahman Khalil, M.D. [3]
Synonyms / Brand Names: BREVIBLOC®
Overview
Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset,[1] a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages.
It is a class II antiarrhythmic.[2]
Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.
Category
FDA Package Insert
BREVIBLOC (esmolol hydrochloride) injection
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
REVIBLOC (Esmolol Hydrochloride) is a beta1-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. BREVIBLOC inhibits the beta1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta2 receptors located chiefly in the bronchial and vascular musculature.
Esmolol and Alcohol
Esmolol hydrochloride is a relatively hydrophilic compound which is very soluble in water and freely soluble in alcohol. Its partition coefficient (octanol/water) at pH 7.0 is 0.42 compared to 17.0 for propranolol.
References
- ↑ Deng CY; Lin SG; Zhang WC; et al. (December 2006). "Esmolol inhibits Na+ current in rat ventricular myocytes". Methods Find Exp Clin Pharmacol. 28 (10): 697–702. doi:10.1358/mf.2006.28.10.1037498. PMID 17235414. Unknown parameter
|author-separator=ignored (help) - ↑ Jaillon P, Drici M (December 1989). "Recent antiarrhythmic drugs". Am. J. Cardiol. 64 (20): 65J–69J. doi:10.1016/0002-9149(89)91203-4. PMID 2688391.